These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8401536)

  • 21. Sensitive detection of p53 mutation: analysis by direct sequencing and multisequence analysis.
    Rozemuller EH; Kropveld A; Kreyveld E; Leppers FG; Scheidel KC; Slootweg PJ; Tilanus MG
    Cancer Detect Prev; 2001; 25(2):109-16. PubMed ID: 11341345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations in the tumor suppressor gene p53 in human liver cancer induced by alpha-particles.
    Andersson M; Jönsson M; Nielsen LL; Vyberg M; Visfeldt J; Storm HH; Wallin H
    Cancer Epidemiol Biomarkers Prev; 1995; 4(7):765-70. PubMed ID: 8672994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.
    Thorlacius S; Börresen AL; Eyfjörd JE
    Cancer Res; 1993 Apr; 53(7):1637-41. PubMed ID: 8453635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments.
    Schlechte HH; Sachs MD; Lenk SV; Brenner S; Rudolph BD; Loening SA
    Cancer Detect Prev; 2000; 24(1):24-32. PubMed ID: 10757120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families.
    Zelada-Hedman M; Børresen-Dale AL; Claro A; Chen J; Skoog L; Lindblom A
    Br J Cancer; 1997; 75(8):1201-4. PubMed ID: 9099970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TP53 gene in blood plasma DNA of tumor patients.
    Schlechte HH; Stelzer C; Weickmann S; Fleischhacker M; Schulze G
    Ann N Y Acad Sci; 2004 Jun; 1022():61-9. PubMed ID: 15251941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study of beta-Thalassemia mutations using the polymerase chain reaction-amplification refractory mutation system and direct DNA sequencing techniques in a group of Egyptian Thalassemia patients.
    El-Gawhary S; El-Shafie S; Niazi M; Aziz M; El-Beshlawy A
    Hemoglobin; 2007; 31(1):63-9. PubMed ID: 17365006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
    Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
    Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations in the mitochondrial DNA D-Loop region occur frequently in human osteosarcoma.
    Guo XG; Guo QN
    Cancer Lett; 2006 Jul; 239(1):151-5. PubMed ID: 16242839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer.
    Ecke TH; Schlechte HH; Gunia S; Lenk SV; Loening SA
    Urol Oncol; 2008; 26(5):470-3. PubMed ID: 18367114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of clinically relevant point mutations by a novel piezoelectric biosensor.
    Dell'Atti D; Tombelli S; Minunni M; Mascini M
    Biosens Bioelectron; 2006 Apr; 21(10):1876-9. PubMed ID: 16388945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 mutation is a common genetic event in ovarian carcinoma.
    Milner BJ; Allan LA; Eccles DM; Kitchener HC; Leonard RC; Kelly KF; Parkin DE; Haites NE
    Cancer Res; 1993 May; 53(9):2128-32. PubMed ID: 8481915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germ-line genetic variation of TP53 in osteosarcoma.
    Savage SA; Burdett L; Troisi R; Douglass C; Hoover RN; Chanock SJ;
    Pediatr Blood Cancer; 2007 Jul; 49(1):28-33. PubMed ID: 17096406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative sequence analysis (CSA): a new sequence-based method for the identification and characterization of mutations in DNA.
    Mattocks C; Tarpey P; Bobrow M; Whittaker J
    Hum Mutat; 2000 Nov; 16(5):437-43. PubMed ID: 11058902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Scanning method to establish the molecular basis of protein C deficiencies.
    Gandrille S; Goossens M; Aiach M
    Hum Mutat; 1994; 4(1):20-30. PubMed ID: 7951255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
    de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
    Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of mutations of neurofibromatosis type 1 gene and N-ras gene in acute myelogenous leukemia.
    Lee YY; Kim WS; Bang YJ; Jung CW; Park S; Yoon WJ; Cho KS; Kim IS; Jung TJ; Choi IY
    Stem Cells; 1995 Sep; 13(5):556-63. PubMed ID: 8528106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines.
    Zheng L; Wang F; Qian C; Neumann RM; Cheville JC; Tindall DJ; Liu W
    Hum Mutat; 2006 Oct; 27(10):1062-3. PubMed ID: 16941491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MEN1 gene mutations in Hungarian patients with multiple endocrine neoplasia type 1.
    Balogh K; Hunyady L; Patocs A; Gergics P; Valkusz Z; Toth M; Racz K
    Clin Endocrinol (Oxf); 2007 Nov; 67(5):727-34. PubMed ID: 17953629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.